Artiva Biotherapeutics, Inc. - Common Stock (ARTV) Institutional Ownership

13F Institutional Holders and Ownership History from Q3 2024 to Q4 2025

Type / Class
Equity / Common Stock
Symbol
ARTV on Nasdaq
Shares outstanding
24,286,350
Price per share
$4.62
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
16,956,116
Total reported value
$72,741,648
% of total 13F portfolios
0%
Share change
-1,377,954
Value change
-$4,402,051
Number of holders
34
Price from insider filings
$4.62
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Artiva Biotherapeutics, Inc. - Common Stock (ARTV) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
venBio Global Strategic Fund III, L.P. 4.9% $2,937,489 1,198,975 venBio Global Strategic Fund III, L.P. 31 Mar 2025
BlackRock, Inc. 2% -62% $714,019 -$1,116,882 485,727 -61% BlackRock, Inc. 30 Jun 2025

As of 31 Dec 2025, 34 institutional investors reported holding 16,956,116 shares of Artiva Biotherapeutics, Inc. - Common Stock (ARTV). This represents 70% of the company’s total 24,286,350 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Artiva Biotherapeutics, Inc. - Common Stock (ARTV) together control 70% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
RA CAPITAL MANAGEMENT, L.P. 41% 9,853,302 0% 0.43% $42,270,666
5AM Venture Management, LLC 9.7% 2,353,304 0% 3.2% $10,095,674
VR ADVISER, LLC 6.6% 1,609,569 0% 0.34% $6,905,051
venBio Partners LLC 2.7% 648,507 -44% 1.3% $2,782,095
FRANKLIN RESOURCES INC 2.1% 520,327 0% 0% $2,232,203
Revelation Capital Management, LLC 1.2% 299,311 0% 1.5% $1,284,044
VANGUARD GROUP INC 1% 246,006 +55% 0% $1,055,366
MILLENNIUM MANAGEMENT LLC 0.89% 217,097 -17% 0% $931,346
BlackRock, Inc. 0.88% 212,538 -28% 0% $911,788
WELLINGTON MANAGEMENT GROUP LLP 0.8% 194,108 0% 0% $832,723
TWO SIGMA INVESTMENTS, LP 0.6% 144,864 +611% 0% $621,467
RENAISSANCE TECHNOLOGIES LLC 0.48% 116,200 +47% 0% $498,498
GEODE CAPITAL MANAGEMENT, LLC 0.42% 101,117 -8.8% 0% $434,132
Alyeska Investment Group, L.P. 0.41% 100,000 0% 0% $429,000
MARSHALL WACE, LLP 0.33% 79,559 0% $341,308
JANE STREET GROUP, LLC 0.17% 40,671 0% $174,479
UBS Group AG 0.15% 36,873 +74% 0% $158,185
STATE STREET CORP 0.15% 35,824 -40% 0% $153,685
BRIDGEWAY CAPITAL MANAGEMENT, LLC 0.14% 35,000 0% 0% $150,150
Scientech Research LLC 0.11% 27,757 0.07% $119,078
MORGAN STANLEY 0.11% 27,072 -37% 0% $116,139
OMERS ADMINISTRATION Corp 0.09% 21,100 0% $90,519
GOLDMAN SACHS GROUP INC 0.05% 12,060 -76% 0% $51,737
PRELUDE CAPITAL MANAGEMENT, LLC 0.04% 10,691 -25% 0% $45,864
Russell Investments Group, Ltd. 0.02% 5,491 0% 0% $23,556

Institutional Holders of Artiva Biotherapeutics, Inc. - Common Stock (ARTV) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 16,956,116 $72,741,648 -$4,402,051 $4.29 34
2025 Q3 18,152,764 $52,098,905 -$149,495 $2.87 39
2025 Q2 18,507,398 $27,946,001 -$5,466,434 $1.51 47
2025 Q1 20,919,533 $62,758,401 -$3,180,578 $3.00 52
2024 Q4 21,161,524 $213,249,951 +$4,226,842 $10.08 57
2024 Q3 20,729,707 $319,393,001 +$306,409,253 $15.45 49